Immunotherapy Before Surgery Improves Skin Cancer Treatment

Patients with high-risk melanoma (type of skin cancer) who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery. These results published today in the New England Journal of Medicine, are from a research study led by the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI).

Use of Immunotherapy in Melanoma

The study demonstrates the same treatment for resectable melanoma given before surgery can generate better outcomes. In this case, researchers used the immune checkpoint inhibitor pembrolizumab.

This treatment relies on the presence of pre-existing T cells coming in contact with cancer cells in the body to generate an immune response, and we found that starting treatment before the melanoma is removed – and with it, the bulk of tumor-specific T cells – leads to a greater response than giving it after surgery.

The mechanism of action of immune checkpoint inhibitors such as pembrolizumab is often described as “taking the brakes off” the immune system’s response to tumor cells.

Researchers hypothesized that there would be a larger anti-tumor immune response and longer immunologic memory if pembrolizumab was administered while the melanoma tumor was still in the body as opposed to after that tumor had been removed when the immune system would be responding primarily to micrometastatic cancer cells.

How Successful is Immunotherapy for Melanoma?

To test this hypothesis, they enrolled 345 participants with stage IIIB through stage IV melanoma that was deemed operable. Participants ages 18-90 were randomized to receive either upfront surgery followed by 200 mg of pembrolizumab every three weeks (adjuvant-only) for a total of 18 doses, or 200 mg of pembrolizumab every three weeks for three doses leading up to surgery (neoadjuvant-adjuvant), then an additional 15 doses following surgery.

The primary endpoint measured was the duration of event-free survival, defined as the time from randomization to the occurrence of one of the following: disease progression or toxicity that resulted in not receiving surgery, failure to begin adjuvant therapy within 84 days of surgery, melanoma recurrence after surgery, or death from any cause.

With a median follow-up of 14.7 months, event-free survival was significantly longer in the neoadjuvant-adjuvant therapy arm, with a hazard ratio of 0.58 when compared to the adjuvant therapy arm, which corresponds to a 42% lower event rate in the patients receiving the neoadjuvant regimen.

Advertisement

The researchers found that the benefit from neoadjuvant therapy was consistent across a range of factors including patient age, sex, performance status, and stage of the disease. They also found that the rates of adverse events (side effects) were similar across both arms of the study and that neoadjuvant pembrolizumab did not result in an increase in adverse events related to surgery.

Based on the findings, patients with high-risk melanoma should start immunotherapy before surgery to generate an immune response while the bulk of the melanoma and the anti-tumor T cells are intact.

Advertisement

Future studies can explore de-escalation strategies for both surgery and adjuvant therapy, as well as approaches for patients whose melanoma does not respond to neoadjuvant therapy.



Source-Eurekalert